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A Stent With Extent—Fiction or Prophecy?
Kobayashi et al. (1) demonstrated the in vivo mechanical proper-
ties of the Radius stent, a self-expanding coronary stent. They
studied the subsequent vessel response over time in a group of 62
patients randomized to either the Radius self-expanding stent or
the Palmaz-Schatz balloon-expandable stent.
Using intravascular ultrasound studies after stent deployment
and at six-month follow-up, the researchers concluded that the
Radius stents continued to enlarge during the follow-up period
(increased 24%) while the Palmaz-Schatz stents had remained
unchanged. The expansion was accompanied by a greater amount
of neointima than the Palmaz-Schatz stents (3.0  1.7 mm2 vs.
1.9  1.2 mm2), resulting in similar late lumen loss in both
configurations.
Our group has been intensively involved in the development of
self-expanding stents, demonstrating the concept of long-term
expansion in animal and clinical models (2–4). In a study pub-
lished in 1999 we reported the first human experience with the
nitinol self-expanding coil stent (5). In a series of 64 patients, we
provided clinical and angiographic data on the effect of self-
expansion during implantation and follow-up. Balloon angioplasty
increased the minimal lumen diameter (MLD) from 1.07 
0.73 mm to 2.24  0.57 mm; stent deployment further increased
the diameter to 2.63 0.48 mm, and within-stent balloon dilation
to 2.96  0.62 mm. Angiographic follow-up showed that the
MLD was 2.15  0.80 mm (late lumen loss of 0.81  0.69 mm),
and the mean stent diameter expanded to 3.58  0.48 mm
(self-expanding late stent gain of 0.62  0.55 mm). The extent of
this expansion was inversely related to the late lumen loss. Several
patients presented a positive remodeling (i.e., their MLD in-
creased at follow-up). A one year, 51 (80%) of 64 patients were
event free.
The self-expanding nitinol stent exerts its acute effect on MLD
through its intrinsic radial force aided by balloon expansion.
Self-expanding stents do not reach their nominal diameter at
implantation. The stent continues to expand until it reaches its
nominal diameter over the follow-up period. The extent of this
expansion is inversely related to the late lumen loss, which may be
due to the continuous injury stimulus by the continued expansion.
The balance between continued expansion and neointimal prolif-
eration determines the late lumen loss, which is the critical
parameter determining long-term stent performance. Kobayashi et
al. (1) do not answer the main question arising from their excellent
study. What is the place of self-expanding stents today, at the start
of the era of the coated balloon-expandable stent?
Based on our results and those of the present study, despite the
promising theoretical benefits of these continued expanding stents
and because of the exaggerated neointimal proliferation, there is no
net late gain compared to balloon-expandable stents. Methods to
reduce intimal proliferation after implantation of self-expanding
stents may include optimal size selection, acute implant method-
ology with respect to pre- and post-stent dilation and in situ
pharmacologic methods to reduce this proliferation. Therefore, the
possible success of such stents in coronary artery disease will
critically depend upon our ability to limit the proliferative response
to that stent. It is timely that a study combining an effective
antiproliferative coating and a self-expanding stent will determine
the role of long-term stent expansion, without the counterproduc-
tive intimal response.
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